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1. Introduction 
Racial factor has been identified as a risk factor of glaucoma. African derived population is 
at higher risk of developing primary open angle glaucoma (POAG). African Americans were 
found to be at greater risk for open-angle glaucoma (Tielsch et al, 1991). The prevalence of 
OAG in populations of African descent was 7-fold greater than in Caucasians age 40–49, but 
due to the steeper increase of OAG in Caucasians at older age, the difference between the 2 
populations dropped to 2.5-fold in the 80–89 year-old age bracket (Quigley et al, 1999). 
Although the prevalence of OAG in Caucasians and Asians aged 40–49 are similar, 
Caucasians as a whole demonstrate a greater prevalence. On the other hand, Asians are 
more predisposed to angle closure glaucoma.  
African derived population is believed to have more severe and progress faster than 
Caucasian with higher rate of blindness (Sommers et al, 1991a; Sommers et al, 1991b). Angle 
closure glaucoma (ACG) behaved differently in Asian population. ACG is responsible in 
more blindness in Asian than in Caucasian population. Laser peripheral iridotomy do not 
confer strong protection in prevention of progression to glaucoma post acute angle closure 
in Asians (Ang and Ang, 2008). African derived population response differently to medical 
and surgical intervention. Racial influence does not only affect susceptibility to glaucoma 
but also response to glaucoma treatment.  
In addition, individual variation has also exerted its effect to management of glaucoma 
patient. Individual variation in drug response poses a significant clinical problem, ranging 
from failure to respond to a drug to life threatening adverse drug reactions. The causative 
factors are genetic, physiological, pathophysiological, and environmental. Quantification of 
pharmacokinetics and pharmacodynamics of topical ophthalmic drugs is technically more 
difficult as compared to systemic drugs. It is considered quite difficult and dangerous to 
obtain aqueous or any ocular fluid sample sequentially to determine the concentration of 
drug in human. Tracer such as technetium makes it possible. Ophthalmic drug once given 
topically is absorbed to systemic circulation directly by passing hepatic first pass effect. Low 
availability of ophthalmic drug in the target tissue may cause the needs for higher 
concentration of the drug and higher likelihood for systemic side effects. The concentration 
of ophthalmic drug in the blood circulation is certainly not reflective the actual 
concentration at the target tissue. The pharmacokinetic of the ophthalmic drug is affected by 
the absorption at the corneal and conjunctiva, rate of blinking, tears concentration and 
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nasolacrimal duct (NLD) system. Moreover, the definitive mechanism of action of 
ophthalmic drug especially pressure lowering drugs are not well understood.  
In general the effectiveness of pressure lowering drugs in glaucoma management is based 
on the amount of pressure reduction. While in longitudinal studies, the progression of 
glaucoma in term of visual field defect or structural changes of optic disc were defined as an 
end point such as in Advanced Glaucoma Intervention Study (AGIS) (The AGIS 
investigators, 2000). The AGIS found that the risk of progression of visual field defects was 
reduced when intraocular pressures (IOPs) were maintained >18mmHg. On another 
longitudinal study, it was suggested lower IOP <15mmHg prevent further progression of 
visual field loss in advanced glaucoma (Shirakashi et al, 1993).  
2. Melanin 
The variation of response was first observed with topical mydriatic drugs; topical 
epinephrine 4% and homatropine 4% in 1971 (Emiru VP). Full mydriasis was observed 
within 40 minutes post instillation of topical epinephrine on the right eye and topical 
homatropine on the left eye in European eyes but much longer time was needed to achieve 
similar effect in African eyes. The amount of melanin was then implicated (Garde et al, 
1978). Melanin is highest in the eye compared to other organ in the body (Potts, 1964). Most 
lipophilic and basic drugs have the ability to bind to the melanin (Leblanc et al, 1998). The 
binding is via electrostatics, van der Waals or simple charge transfer that may reduce the 
effectiveness of drug at the target tissue.  
It is known that Asians and African Americans have larger amount of melanin compared to 
Caucasians. There was no statistical different of the amount of melanin between Asians and 
African Americans but Asians have smaller mean total melanocytes number and mean 
cellularity (Albert et al, 2003). Unlike skin melanocytes, ocular melanocytes are not affected 
by melanin stimulating hormone (MSH). Melanocytes are not mere important to determine 
the iris colour but also perhaps susceptibility of certain ocular disease such as Harada 
disease. Most importantly there is also possible association between melanin and topical 
drug especially pressure lowering drugs. 
For decades, timolol is known as the most effective topical pressure lowering drug in almost 
all type of glaucoma. Timolol has high affinity for and easily bind to melanocyte especially 
isolated melanocytes compare to tissue melanocytes (Menon et al, 1989). Dark-pigmented 
rabbits demonstrated higher concentration of timolol maleate in the iris ciliary body when 
compared to albino rabbits, reducing the amount of active ingredient available for 
pharmacological action (Menon et al, 1989). Menon et al (1989) found that the binding was 
quick at the begining then later decelerated. It is believed the possible binding is achieved 
through van der Waals binding, hydrophobic interaction, ionic interaction and several other 
types of binding. Abrahamson et al (1988) found that the binding of timolol to melanin is 
not proportionate with the release of timolol from the melanin containing tissue. In fact the 
release of melanin into aqueous humour is much faster resulted in higher concentration of 
timolol in the aqueous.  Moreover, the accumulative effect of melanin binding is seen over a 
prolong period of treatment (Salminen and Urtti, 1984). Melanin near to the site of 
pharmacological action did not inactivate the active drug. Paradoxically, melanin 
competitively inhibits timolol. The net effect is that highly pigmented eyes require a higher 
concentration (0.5%) than less pigmented eyes (0.25%), which is reflected in clinical 
observations in Asians and Africans (Ong et al, 2005; Otaleju and Ajayi, 1999; Katz and 
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Berger, 1979).  Caucasians with brown or dark brown irides have higher possibility for 
discontinuation of treatment due to inadequate pressure lowering (Katz and Berger, 1979). 
Perhaps, the variation of respond to management of medical treatment is not entirely due to 
racial differences but more of the amount of iris melanocytes. 
Theoretically, the reversible binding of timolol and melanocytes should provide protective 
effect against the unwanted systemic side effect such as cardiorespiratory impairment. It is 
known that systemic drugs such as systemic beta blockers and antimalarial drugs bind to 
melanin. The binding of timolol and melanin do not confer any protective effect against 
ocular toxicity (Leblanc et al, 1998). However, there is no such study looking into the 
protective effect of melanin binding of topical drugs against unwanted systemic side effect. 
A prospective study on 63 Asians glaucoma patients receiving topical timolol gel forming 
solution for 6 months found that 6 patients developed respiratory outflow obstruction [Selva 
Raja V et al, 2006]. The incidence was only 10% as compared to the previous clinical studies 
in Caucasians (Diggory et al, 1998; Waldock et al, 2000). Diggory and associates (1998) 
reported incidence of 25% and Waldock et al (2000) reported slightly higher incidence of 
28%. However, the former study was using timolol gel forming solution that has longer 
ocular retention and reduced systemic absorption (Hashimoto et al, 2001). Thus direct 
comparison of the possibility of protective effect of melanin bound timolol is not possible.    
Another example is pilocarpine, a parasympathomimetic drug used to treat various type of 
glaucoma especially angle closure glaucoma. Pilocarpine is available in 0.25% to 10% 
concentration. The pressure lowering effect of pilocarpine is observed with concentration of 
1 to 4% in Caucasians or lighter irides individual. African-Americans patients demonstrated 
much lower mean IOP reduction (1.2mmHg) as compared to 2.3mmHg in Caucasian 
patients with pilocarpine 4% (Harris and Galin, 1971). Caucasian with blue coloured iris 
achieved hypotensive effect even with pilocarpine 1%, while those with brown eyes 
required pilocarpine 4% to achieve the similar effect (Harris and Galin, 1971). Higher 
concentration even up to 8% is required in African-American to achieve similar effect 
(Harris and Galin, 1971). The effect of melanin to pilocarpine is not extensively studied but it 
is a strong postulation that pilocarpine has similar affinity towards melanin (Meilikian et al, 
1971). Inactivation of pilocarpine was more pronounced (2-3 folds more) in pigmented uveal 
tissue compared to albino tissue (Lyons and Krohn, 1973). 
Brominidine, an alpha agonist is effective as adjunctive, combination and replacement 
therapy in glaucoma management. Brominidine provide significant pressure lowering effect 
in various type of glaucoma and in various populations (Adkins and Balfour, 1998).A post 
hoc analysis was conducted on 460 patients involved in multicenter open label control trial 
to determine the effectiveness of brominidine as replacement therapy (Lee, 2000). African-
Americans and Hispanic patients demonstrated better IOP reduction and almost similar to 
Caucasians with green or hazel eye colour. Brominidine is most effective as replacement 
therapy in Caucasians with green or hazel irides but less effective in Asian patients with 
mean IOP reduction of 1.54mmHg (Lee, 2000). In contrary, the pressure reduction of 
brominidine as monotherapy was almost similar to other populations based on a 
randomized control trial conducted in Taiwanese patients (Chen et al, 2003). A 
pharmacokinetics study was conducted on albino and pigmented rabbits using 14C-
brominidine solution (Acheampong et al, 1995). The absorption of brominidine was rapid at 
the rate of 0.67 hour in both pigmented and albino rabbits. The half life was just 1 hour for 
both pigmented and albino rabbits but followed by slower declined in pigmented rabbits. 
The terminal half-life in pigmented rabbit was 160 hours suggesting the high affinity of 
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brominidine towards melanin-containing tissue (Acheampong et al, 1995). Clinically, 
brominidine was found to be as effective as timolol 0.5% but with safer systemic profile; 
minimum effect on the cardiorespiratory system.  
On the other hand, pressure lowering drugs are also found to induce pigmentation and 
melanin deposition. Melanin deposition (adenochrome) on the conjunctival is a common 
side effect with topical epinephrine. In certain extreme cases, the deposition melanin even 
causes blockage of lacrimal sac and ‘black cornea’ (Barishak et al, 1969; Kaiser et al, 1992). 
Black cornea is deposition of melanin in the cornea usually occurs in prolong treatment with 
epinephrine (Kaiser et al, 1992). The deposition is unwanted side effect without 
compromising the effectiveness of epinephrine as pressure lowering drug (Corwin and 
Spencer, 1963).  There is no racial different in the tendency of melanin deposition. The 
effectiveness of dipivefrin in African-American patients was almost similar to Caucasians 
(Drake et al, 1993).  
Topical prostaglandin analogues are currently replacing topical beta blockers as the first line 
drug in glaucoma management. Unlike timolol or any topical beta blockers, prostaglandin 
analogues do not bind to melanin. Instead, darkening of the iris, eyelashes and even eyelids 
were reported.  This peculiar side effect was first noted in monkeys during the pre-clinical 
trial of latanoprost (Bito, 1997). Latanoprost is among the first commercially available topical 
prostaglandin analogue in the market. Iris darkening was initially observed to be more 
prominent in those with mixed colouring of hazel irides especially those with brown 
patches on blue, gray, green or yellow (Watson and Stjernschantz, 1996). As the popularity 
of latanoprost escalated and spread to all part of the world, iris darkening was also found in 
homogenous dark brown irides of Japanese and South East Asians (Chiba et al, 2004; Chou 
et al, 2005).  
The mechanism of prostaglandin induced iridial pigmentation (PIIP) is not clear. Three 
possible mechanisms have been widely discussed; increased in iris stromal melanocyte 
numbers, increased melanogenesis and redistribution iris stromal melanocytes to the 
anterior border region without increasing number of melanocytes or melanin (Watson and 
Stjernschantz, 1996; Grierson et al, 2001; Cracknell et al, 2007). It was also noted that 
incidence of PIIP is time dependant; PIIP tends to occur within the first 8 months post 
initiation of treatment. After 2 years, over 90% of those that are going to develop iris 
darkening have already done so (Alm et al, 2004). After 3 years there was no evidence of 
increase in pigmentation (Alm et al, 2004). Older patients were more at risk to develop PIIP 
(Arranz-Marquez and Teus, 2007). However, to our knowledge, there is no evidence that the 
effectiveness of prostaglandin analogues is affected by the presence of PIIP. The 
effectiveness of latanoprost was also not affected by the iris colour. Those with blue, brown 
and hazel irides demonstrated almost similar pressure lowering effect (Bayer et al, 2005). 
PIIP remains as cosmetic concern rather than functional, although it is indeed affect the 
persistency and adherence to medications. Unlike PIIP, the severity of conjunctival 
hyperaemia induced by latanoprost is associated with significant better IOP reduction 
(Kobayashi and Kobayashi, 2011). Conjunctival hyperaemia can be used as predictor of 
effectiveness of topical latanoprost.  
A pooled data analysis of eight different clinical trials involving African-Americans, Asians, 
Caucasians and Mexicans glaucoma patients was conducted to compare the pressure 
lowering effect between latanoprost and timolol (Hedman and Larsson, 2002). Latanoprost 
reduced mean diurnal pressure more than timolol. A significant greater difference in mean 
diurnal pressure between latanoprost and timolol was observed in the Asian and Mexican 
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patients than European and American patients (Hedman and Larsson, 2002). Comparatively 
lack of effectiveness of timolol in Asian and Mexican patients was postulated due to 
reversible timolol and melanin binding. The mean diurnal pressure of African-American 
patients was almost similar to the Caucasian. Travaprost is found to be more effective in 
African-American compared to latanoprost and timolol (Netland et al, 2001). 
In vitro spectrometric and in vivo study was conducted on timolol, betaxolol, carteolol, 
pilocarpine, epinephrine, prostaglandin A2, F2 alpha and E2 analogues to determine the 
binding ability of drug to synthetic melanin on pigmented and non-pigmented rabbits 
(Nagata et al, 1993). Beta blockers exhibited the highest binding rate of 80 to 85% followed 
by epinephrine 50% and pilocarpine 40%. Binding of prostaglandin analogues and synthetic 
melanin was almost absent. As expected, significant IOP reduction was observed in albino 
rabbits treated with timolol 0.5% and pilocarpine 3% compared to pigmented rabbit. 
Epinephrine 1% was effective in both pigmented and albino rabbits but with slightly better 
effect on albino rabbits. Prostaglandin analogues provide good pressure reduction on 
pigmented and albino rabbits. Based on this animal experimental study, the binding of 
pressure lowering drugs to melanin is a strong predictor to predetermine the effectiveness 
of the drugs in lowering the pressure in different population. Thus, iris colour plays an 
important role in selecting the drug of choice in glaucoma management of certain 
population. Table 1 provide a summary of possible interaction between drug and melanin. 
For example timolol 0.25% is certainly not a good choice for first line management in Asians. 
However, prostaglandin analogue is indeed a better choice in achieving target pressure. 
 
Drug 
Drug-melanin 
interaction 
Implications 
Beta blockers 
Timolol 
Betaxolol 
Reversible binding Higher concentration in pigmented iris 
Parasympatomimetics 
Pilocarpine 
Reversible binding Higher concentration in pigmented iris 
Alpha agonists 
Brominidine 
Reversible binding 
Less effective in pigmented iris 
 
Adrenergic 
Dipivefrin 
Deposition of 
melanin 
Adenochrome 
Prostaglandin analog 
Latanoprost 
Travaprost 
Induced 
pigmentation 
Side effect- prostaglandin induced iris 
pigmentation (PIIP) 
Table 1. The possible interaction between topical pressure lowering drugs and melanin 
3. Genetics and pharmacogenetics 
Drug interaction with Melanin may explain the racial variation of drug respond but not 
individual respond in the population. Individual variation in drug response poses a significant 
clinical problem, ranging from failure to respond to a drug to life threatening adverse drug 
reactions. The possible causative factors include genetic, physiological, pathophysiological, 
and environmental. Genetics play an important role in drug absorption, distribution, 
metabolism, and drug-drug interactions. Although genetics is believed to play a major role, it 
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is interrelated with other causative factors. It is estimated that genetics is responsible for 15–
30% of variation in drug responsiveness (Evan and McLeod, 2003). However, in certain drugs, 
genetic factors could contribute up to 95% of variation. Pharmacogenetics aims to understand 
how genetic variations contribute to variations in response to medicines.  
Genetic variations may influence drug action by affecting its pharmacokinetics, which 
includes absorption, distribution, metabolism, and excretion, or its pharmacodynamic 
properties (what the drug does to the body), which involves target receptors, enzyme 
targets, and disease modifiers. Single nucleotide polymorphisms (SNPs) are naturally 
occurring variations that may not cause disease but are responsible in altering the products 
they encode and have a reported frequency of more than 1% of the population (Ford, 1940). 
The variations in all genes are believed to cause different individuals or populations to 
express different forms of proteins also known as gene products, including those 
responsible for metabolizing the drug or the site of drug action. Genes encoding drug 
transporters were also identified as potential factors causing alteration in drug response 
(Evans and McLeod, 2003).  
The variation of drug response can be divided into Gaussian variation and monogenic (all-
or-none) variation. The initial understanding of pharmacogenetics is based on monogenic 
variation (all-or-none); the impact of a single gene product may lead to all-or-none 
responsiveness (Kalow, 1997). Gaussian variation is a mathematically calculated variation in 
the form of median effective or lethal dose of a drug (ED50 or LD50) and determined mainly 
by environmental factors but with hereditary elements (Vesell, 1992; Trevan, 1927). The 
principle is based on a distribution curve of the frequency of response to a standard drug 
dose in a group of individuals. A majority of the known drugs demonstrate a unimodal 
distribution similar to a bell-shaped or Gaussian curve (Turner et al, 2001). Gaussian 
distribution represents the effect of multifactorial determinants by interaction of genetic and 
environmental factors without any single factor having a discernibly large effect on the 
response. Thus, it is more difficult to identify the effects of individual genes. Bimodal 
distribution is due to separate subpopulations with distinctly different drug responses 
suggesting that a single factor, possibly segregation of alleles at a single genetic locus, has a 
large effect on drug response (Murphy, 1964). Responders and non-responders to a certain 
drug may be represented as a bimodal distribution curve (McLaren and Moroi, 2003).  
Pharmacogenetics is potentially important in customizing or personalizing medication. 
Tailoring the medication according to the predicted response, minimizing the side effects, 
and maximizing the expected drug response is ideal to promote compliance and persistency 
of medication especially in chronic diseases. ‘Candidate gene’ or ‘candidate pathway’ 
approaches have been adopted to predict the disposition or response to a given drug. So far, 
polymorphisms are the most studied genetic variations. Polymorphisms can be 
homozygous or heterozygous, depending on how many copies of a variant or wild-type 
allele are present. Based on the balanced polymorphism concept, a double dose of a variant 
allele (homozygous mutant) may exert a detrimental effect but a single copy may increase 
fitness (heterozygous mutant) (Ford, 1940).  
However, the concept of single gene has been left behind in the pharmacogenetics field. The 
drug-response phenotype is not governed by a single gene (monogenic trait) but by multiple 
genes (polygenic) that has spawned the term ‘pharmacogenomics’. The effects of most drugs 
are determined by many proteins and composite genetic polymorphisms in multiple genes 
coupled with non genetics factors are postulated to be responsible in drug response. For 
example; HT3 antagonist tropisetrone, a CYP2D6 substrate if given to patient with high 
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enzyme activity due to gene duplication will not achieve effective drug concentrations. 
Inability to achieve effective drug concentration is not entirely due to the CYP2D6 
polymorphism but may be due to other factors influencing the entire pathway before 
reaching the target organ or tissue. As HT3 antagonist is also a phagocytic glycoprotein 
(Pgp) substrate, the level of Pgp expression will affect ability of HT3 anatgonist to transfer 
from blood to the brain. Once the drug reach the HT3 receptor, the magnitude of response 
will depend on the drug concentration, neurotransmitter concentration in the synaptic cleft 
and genetic polymorphisms of the receptor. Moreover, serotonin concentration is further 
influenced by proteins involved in biosynthesis, transport and catabolism. Thus, the 
pharmacogenetic analysis of poor response to HT3 antagonist should include all of these 
candidate genes that involved in the pathway of this drug before reaching the target tissue.   
The impact of polymorphisms of cytochrome P450 (CYP) enzymes and thiopurine 
methyltransferase (TPMT) are the most established and well studied (Idle and Smith, 1979). 
Cytochrome P450s are a multi-gene family of enzymes found predominantly in the liver, the 
most important site for metabolic elimination of most drugs. Cytochrome P450 CYP2D6 
(known as debrisoquine hydroxylase), CYP2C9, and CYP2C19 are among the most studied 
cytochrome P450s and affect the metabolism of 20–30% of clinically used drugs (Kirchheiner 
et al, 2004; Kirchheiner and Brockmoller, 2005).  
Polymorphisms in CYP2D6 result in different metabolic capacities for antidepressants, anti-
hypertensives such as ǃ-blockers, and antipsychotic drugs. Some mutations in CYP2D6 
result in complete loss of enzyme activity and severely compromises drug metabolism; this 
is known as the ‘poor metabolisers’(PMs) phenotype.Other mutations or duplications of 
CYP2D6 produce increased metabolic capacity; individuals with such variation are known 
as ultra-rapid metabolisers (UMs). Those with wild-type levels of activity are known as 
extensive metabolisers (EMs). PMs require low doses of a drug or higher doses if it is a 
prodrug, while UMs and EMs require higher doses or a more frequent dose administration 
regime. An individual can be a PM of one drug and EM of another. There is evidence of 
racial influence in phenotypic of CYP2D6. It is believed due to the effect of selective 
breeding rather than direct racial influence. CYP2D6 PMs were found in 6–10% of 
Caucasians, fewer in African populations (5%), and even fewer in Asians (less than 1%) 
(Kalow, 1991; Marez et al, 1997; Masimirembwa et al, 1993).  
Pharmacogenetics studies have been conducted with various systemic drugs but minimal 
emphasis has been given to topical ophthalmic drugs. Timolol can be given orally as in 
hypertensive treatment and CYP2D6 polymorphisms are known to affect the metabolism of 
oral timolol. In spite of given topically, timolol especially in the aqueous form has poor 
ocular bioavailability due to large amount (up to 80%) of topical timolol is absorbed to 
systemic circulation upon instillation through nasal mucosa (Shell, 1982). High systemic 
absorption of topical timolol is based on clinical observation of the fellow untreated eye that 
demonstrated lesser but significant IOP reduction (Zimmerman and Kaufman, 1977). It is 
most significantly, explained the systemic adrenergic beta-blocking that result in life-
threatening side effect such as bradycardia and respiratory impairment in certain 
susceptible individuals (Zimmerman and Kaufman, 1977; Zimmerman et al, 1983). A drop 
of 0.5% timolol aqueous solution to each eye is approximates to a 10mg oral dose. The 
hepatic metabolism is important in pharmacokinetic of topical timolol. Naturally, CYP2D6 
play a role in pressure lowering effect as well as cardiopulmonary side effect of topical 
timolol.  
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Edeki and co-workers (1995) was among the first investigators attempted to determine the 
role of CYP2D6 in the metabolism of topical timolol. Topical timolol was instilled through 
the nose to ensure no spill-over of the medication through eye drop application in a known 
EMs and PMs. Oral quinidine was also given as CYP2D6 inhibitor to EMs randomly. Plasma 
timolol concentration was significantly higher in PMs compared to EMs suggesting the role 
of CYP2D6 in metabolism of topical timolol. Greater heart rate reduction and higher plasma 
timolol concentration was observed in EMs, signified not only the importance of CYP2D6 in 
timolol metabolism but the possibility of oral-ophthalmic drug interactions. Nasal 
instillation of topical timolol in this study may not represent the actual clinical situation; 
overestimation of the oral-ophthalmic interaction is inevitable. Additional reduction of heart 
rate and IOP was also observed in 12 healthy Japanese volunteers who were given oral 
cimetidine (CYP2D6 inhibitor) prior to topical timolol instillation (Ishii et al, 2000). This 
finding further reaffirms the role of CYP2D6 in topical timolol metabolism. 
CYP2D6 gene has been extensively studied in various populations and is known to be 
highly polymorphic. Arg296Cys (rs16947) and Ser486Thr (rs1135840) has been widely 
studied. The polymorphism of CYP2D6 is commonly pooled together and defined based on 
the functional activity such as EMs, intermediate metabolisers (IMs), PMs and UMs. There is 
no conclusive definition, which further complicate the analysis. A pilot genotype-phenotype 
study was conducted on glaucoma patients and healthy volunteers instilled with timolol 
aqueous solution and hydrogel 0.1% (Nieminen et al, 2005). The CYP2D6 PMs had higher 
maximum plasma concentrations, longer elimination half lives and higher area-under-curve 
than EMs, IMs and UMs. However, this effect was not significant in those treated with 
timolol hydrogel 0.1%. Theoretically, PMs should have poorer pressure reduction. 
Surprisingly, CYP2D6 polymorphisms were not associated with meaningful pressure 
reduction of timolol based on the finding from Marshfield Clinic Personalized Medicine 
Research project (PMRP) (McCarty et al, 2008). Marshfield Clinic PMRP is a population-
based bio bank project that has extensive medical record for phenotyping and stored DNA 
for genotyping. The meaningful pressure reduction was defined as IOP reduction of more 
than 20% from the baseline pressure. Similar finding was also noted in Asian populations 
(Yuan et al, 2010). There was no significant different between CYP2D6 SNPs rs16947 and 
rs1135840 with mean IOP reduction 24 hours post topical timolol instillation. Contradicting 
evidence was found in the previous study from the same group of investigators using 
different laboratory technique; CYP2D6 rs16947 TT genotype was associated with poor 
timolol-induced ocular hypotensive effects (Yang et al, 2009). There was no significant 
different between the findings of two different laboratory technique but the later study 
(Yuan et al, 2010) recruited more subjects. Most likely by chance more subjects with rs16947 
polymorphism and those with poorer respond to timolol were recruited. However, 
consistently both studies found that timolol-induced bradycardia was significantly 
associated with rs16947 CT and TT phenotypes (Yuan et al, 2010; Yang et al, 2009).  
CYP2D6 rs16947 plays a role on inter-individual difference of timolol-induced side effect. 
Evidently, CYP2D6 is a potential pharmacokinetic candidate gene in predicting the 
susceptibility to timolol-induced bradycardia. Detection of CYP2D6 can be done with ease 
and inexpensive. Customizing the prescription of timolol according to polymorphism of 
CYP2D6 will promote compliance and prevent life threatening side effect. Timolol is a non-
selective beta adrenergic antagonist but acts more on beta 2 receptor. Although the 
mechanism of action of timolol and other beta antagonist is unclear, it is believed to act on 
beta adrenergic receptor particularly in the ciliary body. Since beta adrenergic agents play a 
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significant role in IOP regulation, the presence of beta adrenergic receptor in ocular cells is 
of physiological and clinical importance (Nathanson, 1981). Both beta 1 (ADRB1) and beta 2 
(ADRB2) adrenergic receptors are present in the ciliary body and trabecular meshwork with 
predominantly beta 2 (Wax and Molinoff, 1987). The reversible binding of beta antagonist 
prevents binding of catecholamine that in turn prevents activation of intracellular adenylate 
cyclase and reduces the intracellular concentration of cAMP at the ciliary body. Through an 
unknown mechanism, this process reduces aqueous humour production (Neufeld, 1979). 
The basal level of cAMP is maintained, as is the response to other transmitters. cAMP is an 
important second messenger in the intracellular cascade. Since the understanding of 
aqueous humour production is imprecise, the mechanism of action of topical beta antagonist 
remains unknown.  
Beta adrenoreceptor gene (ADRB) controls the function of receptor. Any polymorphism or 
mutation of ADRB is certainly affecting drug-receptor binding and function. Beta2 
adrenoreceptor gene (ADRB2) has been widely studied in hypertension, cardiovascular, 
respiratory and other diseases. Thus so far, 20 important SNPs were found in ADRB2 but 
only certain SNPs were functionally important (Table 2). In addition, the frequency of the 
SNPs differs according to population (Table 2). The phenotype of ADRB2 is based on the 
effect of beta agonist on ADRB2 receptor.  
 
Codon Amino
Acid 
SNP Caucasians African Asian Latino Phenotype 
-20 
 
-47 
 
 
 
46 
 
 
 
79 
 
 
 
491 
 
 
-19 
Arg 
Cys 
 
16 
Arg16 
Gly16 
 
27 
Gln27 
Glu27 
 
164 
Thr164 
Ile164 
 
T>C 
 
C>T 
 
 
 
A>G
 
 
 
C>G 
 
 
 
C>T 
NA 
 
 
65.0** 
35.0 
 
 
45.7* 
54.3 
 
 
65.2* 
34.8 
 
 
96.0@ 
4.0 
NA 
 
 
79.0** 
21.0 
 
 
48.8* 
51.2 
 
 
79.3* 
20.7 
 
 
98.0@ 
2.0 
NA 
 
 
92.0** 
8.0 
 
 
58.7* 
41.3 
 
 
92.8* 
7.2 
 
 
99.0@ 
1.0 
 
NA 
 
 
82.4# 
17.6 
 
 
57.9# 
42.1 
 
 
NA 
 
 
 
97.0@ 
3.0 
Increased 
expression 
 
Increased 
expression 
 
 
 
 
Increased 
desensitization 
 
 
Reduced 
desensitization 
 
 
 
Reduced coupling 
*Xie et al, 1999; #Litonjua et al, 2004; **McGraw et al, 1998; @Small et al, 2003 
NA: not available 
Table 2. Allele frequencies and possible phenotypes of ADRB2 polymorphisms  
It was found that polymorphism of beta 2 adrenergic receptor gene (ADRB2) was not 
responsible in susceptibility to glaucoma in Caucasian, African, Turkish and Japanese 
population (McLaren et al, 2007; Güngör et al, 2003; Inagaki et al, 2006). Although, it was 
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found those with Gly16 was associated with POAG at younger age and higher baseline IOP 
with 27Glu in Japanese population (Inagaki et al, 2006). It was then postulated that 
polymorphisms of ADRB2 may play a role in predicting the effectiveness of beta blocker. 
Fushjager et al (2005) conducted a study on 270 healthy non smoking Caucasian males. 
Topical timolol was instilled and IOP was taken at 8, 12 and 16 hours post instillation. 
Genotype for ADRB2 was also done using allele-specific real time PCR to detect 
polymorphisms at codon 16 and 27. There was no association of ADRB2 polymorphisms at 
codon 16 and 27 with short term ocular hypotensive effects of topical timolol. However, this 
study was conducted on healthy individual that may not represent glaucoma patients. 
Furthermore, the IOP was taken for such a short period. 
Marshfield Clinic PMRP conducted a similar study on 210 Caucasian glaucoma patients 
who were treated with topical timolol and defined meaningful IOP reduction as more than 
20% from the baseline. Homozygous wild CC for codon 27 was significantly associated with 
good pressure lowering effect of timolol (lmore than 20% reduction from the baseline). 
Gln27Glu was associated with 2-fold greater odds of a clinically meaningful IOP (McCarty 
et al, 2008). Another study in Asian population found that Arg16Gly of ADRB2 was 
associated with pressure lowering effect of timolol (Liza Sharmini, 2011).  Gly16 of ADRB2 
was also found to increase the risk of respiratory impairment and T-20C was found to confer 
protective effect against respiratory impairment in a study involving 63 Asian glaucoma 
patients [Selvaraja, 2006]. Evaluation of respiratory function was conducted 6 months post 
instillation of topical timolol-XE 0.5% in newly diagnosed non-smoker glaucoma patients. 
ADRB2 is not only important in predicting the efficacy of timolol but a good predictor for 
the side effect of timolol. The current available research findings highlight the potential of 
ADRB2 as pharmacodynamic candidate gene. However, more research work is needed 
especially to study the potential tagging markers of CYP2D6 and ADRB2 in predicting the 
efficacy of timolol. 
Since timolol is non-selective beta blocker antagonist, the potential role of ǃ1 
adrenoreceptor gene (ADRB1) polymorphisms was also studied on patients treated with 
topical timolol (Nieminen et al, 2005).There was no association between Arg389Gly and 
Ser49Gly polymorphism to the side effect of timolol aqueous and gel form. Reduction of 
heart rate, systolic and diastolic blood pressure in supine, upon head-up tilt or during 
exercise was not associated with ADRB1. Lack of effect as potential pharmacodynamic 
predictor is due to the lesser effect of timolol on ǃ1 compared to ǃ2 receptor. The potential 
role of ADRB1 polymorphism is best studied in betaxolol, a cardioselective topical beta 
blocker acts on ADRB1 receptor. Betaxolol is more protective against cardiorespiratory 
side effects but less efficacious compared to timolol. In a small pilot study involving 48 
healthy volunteers treated with betaxolol hydrochloride 0.5% for 6 weeks, polymorphism 
at codon 389 (Arg389) of ADRB1 was found to be associated with significant IOP 
reduction from baseline (Schwartz et al, 2005). In fact, those with Arg389 recorded higher 
baseline IOP. However, in a larger study on 210 glaucoma patients in Marshfield Clinic 
PMRP, ADRB1 failed to show any significant association with meaningful IOP reduction 
(McCarty et al, 2008). The role of ADRB1 in effectiveness of topical beta blocker is still 
inconclusive. Similarly, in spite of extensive studies on ADRB1 and ADRB2 in systemic 
diseases especially in hypertension and asthmatic patients, the possible association is still 
inconclusive. The population variation in allele frequency of ADRB1 and ADRB2 
polymorphisms is perhaps the major contribution. 
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Prostaglandin analogues have gained popularity recently and replacing topical beta 
blockers as first line drug in many countries. Currently, there are at least 3 major popular 
prostaglandin analogues that act on prostaglandin receptors. Latanoprost and travaprost act 
on FP receptor that regulate by prostaglandin F2ǂ receptor gene (PTGFR), while bimatoprost 
acts on EP receptor. EP receptor is regulated by prostaglandin E2 receptor gene.  Thus, 
PTGFR is potentially a pharmacodynamic candidate gene that may be associated with 
pressure lowering effect and side effect of latanoprost. Most of the studies on PTGFR were 
conducted in myometrium and corpus luteum to understand the contractility of uterus as 
well the effect of prostaglandin agonist on myometrium especially pre-term labour. 
Screening of PTGFR in 100 Japanese healthy volunteers found 10 single nucleotide 
polymorphisms in the promoter, coding and non-coding region (Sakurai et al, 2007). Two 
SNPs rs3753380 at the promoter region and rs3766355 at introns 1 (non-coding region) were 
found to significantly associated with meaningful IOP reduction of more than 20% from 
baseline post instillation of topical latanoprost. In a pilot study of 30 Asian glaucoma 
patients receiving topical latanoprost as an adjuctive therapy to topical timolol, the genetic 
polymorphism in the coding region of PTGFR was not associated with the level of HLA-DR 
on conjunctival impression cytology. HLA-DR level is a good predictor in subconjunctival 
inflammation as well as conjunctival hyperaemia induced by topical latanoprost [Cheong, 
2007]. 
Currently, there are a number of on-going studies on the pharmacogenetics of topical 
antiglaucoma drugs. The potential role of genetics polymorphism in predicting the 
effectiveness and side effects of topical antiglaucoma drug is undeniable but strong 
powerful scientific evidences are needed to further support this observation.  
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